7-t-butyldimethylsilyl-10-hydroxycamptothecin
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2010 (NCT01202370)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Topoisomerase IINHIBITOR
Topoisomerase I inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 1h-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4h,12h)- dione, 11-((1,1-dimethylethyl)dimethylsilyl)-4-ethyl-4,9- dihydroxy-, (4s)-
- 7-t-butyldimethylsilyl-10-hydroxycamptothecin
- 7-t-butyldimethylsilyl-10-hydroxycamptothecin
- 7-t-butyldimethylsilyl-10-hydroxycamptothecin
- 7-tert-butyldimethylsilyl-10-hydroxycamptothecin
- ar 67 cpd
- ar-67 cpd
- db 67
- db-67
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01202370 | Phase 1 | Sep 1, 2010 | Arno Therapeutics, University of Kentucky |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arno Therapeutics | For profit | 1 | 0 | 1 | 2010 |
| University of Kentucky | Academic/Hospital | 1 | 1 | 1 | 2010 |
2 organizations
Page 1 / 1